Ninlaro (Ixazomib Citrate)

• Ninlaro is used in the treatment of multiple myeloma, a plasma‑cell cancer, as part of combination regimens.
• Multiple myeloma (first‑line, in combination with lenalidomide and dexamethasone): provides an oral proteasome inhibition option that improves progression‑free survival.
• Multiple myeloma (relapsed or refractory after prior therapy): added to standard regimens to achieve deeper responses and extend disease control.
• Multiple myeloma (combined with other antimyeloma agents): contributes to overall response rates when incorporated into multi‑drug protocols.

• Ixazomib citrate reversibly binds to the catalytic β5 subunit of the 20S proteasome, inhibiting its chymotrypsin‑like activity. This blockade prevents degradation of polyubiquitinated proteins, leading to intracellular accumulation, disruption of cellular homeostasis, and induction of apoptosis in malignant plasma cells. The oral formulation allows systemic exposure sufficient to achieve proteasome inhibition comparable to injectable agents. By targeting the proteasome pathway, ixazomib interferes with multiple signaling cascades essential for tumor cell survival.

Ixazomib citrate may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea
• Diarrhea
• Fatigue
• Thrombocytopenia
• Peripheral neuropathy
• Constipation

Serious or Rare Side Effects

• Neutropenia
• Severe infections (e.g., pneumonia)
• Pulmonary embolism
• Cardiac failure or arrhythmia
• Tumor lysis syndrome
• Severe cutaneous reactions (e.g., Stevens‑Johnson syndrome)

When prescribing Ninlaro, clinicians should observe several safety precautions to minimize risk.

• Monitor blood counts: perform regular CBC tests to detect cytopenias early.
• Assess hepatic function: evaluate liver enzymes before initiation and during therapy.
• Evaluate infection risk: screen for active infections and treat promptly.
• Avoid in patients with known hypersensitivity: discontinue if allergic reactions occur.
• Pregnancy and lactation: use only if benefits outweigh risks; data are limited.
• Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Ixazomib citrate can interact with other medicines, affecting its plasma levels or safety profile.

Major Interactions (Avoid)

• Strong CYP3A inducers (e.g., rifampin, carbamazepine): markedly reduce ixazomib exposure.
• Strong CYP3A inhibitors (e.g., ketoconazole, itraconazole): increase ixazomib concentrations and toxicity risk.
• Anticoagulants (e.g., warfarin): may enhance bleeding; monitor coagulation parameters closely.

Moderate Interactions (Monitor Closely)

• P‑gp inhibitors (e.g., verapamil, amiodarone): may raise ixazomib levels modestly.
• Certain antiepileptics (e.g., phenytoin): can alter metabolism, requiring dose adjustments.
• Live vaccines: reduced efficacy; consider timing relative to therapy.